Jiang Dadi, Turner Brandon, Song Jie, Li Ruijiang, Diehn Maximilian, Le Quynh-Thu, Khatri Purvesh, Koong Albert C
Stanford University School of Medicine, Stanford, CA.
Stanford Center for Biomedical Informatics Research, Stanford University, Stanford, CA.
JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00073. Epub 2017 Jul 26.
Triple-negative breast cancers (TNBCs) are associated with a worse prognosis and patients with TNBC have fewer therapeutic options than patients with non-TNBC. Recently, the IRE1α-XBP1 branch of the unfolded protein response (UPR) was implicated in TNBC prognosis on the basis of a relatively small patient population, suggesting the diagnostic and therapeutic value of this pathway in TNBCs. In addition, the IRE1α-XBP1 and hypoxia-induced factor 1 α (HIF1α) pathways have been identified as interacting partners in TNBC, suggesting a novel mechanism of regulation. To comprehensively evaluate and validate these findings, we investigated the relative activities and relevance to patient survival of the UPR and HIF1α pathways in different breast cancer subtypes in large populations of patients.
We performed a comprehensive analysis of gene expression and survival data from large cohorts of patients with breast cancer. The patients were stratified based on the average expression of the UPR or HIF1α gene signatures.
We identified a strong positive association between the XBP1 gene signature and estrogen receptor-positive status or the HIF1α gene signature, as well as the predictive value of the XBP1 gene signature for survival of patients who are estrogen receptor negative, or have TNBC or HER2. In contrast, another important UPR branch, the ATF4/CHOP pathway, lacks prognostic value in breast cancer in general. Activity of the HIF1α pathway is correlated with patient survival in all the subtypes evaluated.
These findings clarify the relevance of the UPR pathways in different breast cancer subtypes and underscore the potential therapeutic importance of the IRE1α-XBP1 branch in breast cancer treatment.
三阴性乳腺癌(TNBC)的预后较差,与非三阴性乳腺癌患者相比,TNBC患者的治疗选择较少。最近,基于相对较小的患者群体,未折叠蛋白反应(UPR)的IRE1α-XBP1分支与TNBC的预后相关,提示该通路在TNBC中的诊断和治疗价值。此外,IRE1α-XBP1和缺氧诱导因子1α(HIF1α)通路已被确定为TNBC中的相互作用伙伴,提示一种新的调控机制。为了全面评估和验证这些发现,我们在大量患者中研究了UPR和HIF1α通路在不同乳腺癌亚型中的相对活性及其与患者生存的相关性。
我们对来自大量乳腺癌患者队列的基因表达和生存数据进行了综合分析。根据UPR或HIF1α基因特征的平均表达对患者进行分层。
我们发现XBP1基因特征与雌激素受体阳性状态或HIF1α基因特征之间存在强正相关,以及XBP1基因特征对雌激素受体阴性、TNBC或HER2患者生存的预测价值。相比之下,另一个重要的UPR分支,即ATF4/CHOP通路,总体上在乳腺癌中缺乏预后价值。HIF1α通路的活性与所有评估亚型中的患者生存相关。
这些发现阐明了UPR通路在不同乳腺癌亚型中的相关性,并强调了IRE1α-XBP1分支在乳腺癌治疗中的潜在治疗重要性。